Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.

MLA

de Almeida, Daniel Vargas P., et al. “Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.” Journal of Immunotherapy and Precision Oncology, vol. 6, no. 4, Dec. 2023, pp. 162–69. EBSCOhost, https://doi.org/10.36401/JIPO-23-9.

APA

de Almeida, D. V. P., Anderson, J. M., Danila, D. C., Morris, M. J., Slovin, S. F., Abida, W., Cohn, E. D., Baser, R. E., Scher, H. I., & Autio, K. A. (2023). Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. Journal of Immunotherapy and Precision Oncology, 6(4), 162–169. https://doi.org/10.36401/JIPO-23-9

Chicago

de Almeida, Daniel Vargas P, Justine M Anderson, Daniel C Danila, Michael J Morris, Susan F Slovin, Wassim Abida, Erica D Cohn, Raymond E Baser, Howard I Scher, and Karen A Autio. 2023. “Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.” Journal of Immunotherapy and Precision Oncology 6 (4): 162–69. doi:10.36401/JIPO-23-9.